Marilena Cesari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marilena Cesari has a total of 286 co-authors. Here are the top co-authors by number of shared publications:
- Emanuela Palmerini
Osteoncology, Soft Tissue and Bone Sarcomas, Innovative Therapy Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
38 shared publications - Alessandra Longhi
Osteoncologia, Sarcomi Ossei e Dei Tessuti Molli e Terapie Innovative IRCCS Istituto Ortopedico Rizzoli Bologna Italy
26 shared publications - Marco Gambarotti
Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
19 shared publications - Davide Donati
Clinica Ortopedica e Traumatologica III a Prevalente Indirizzo Oncologico, Musculoskeletal Oncology Department, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
18 shared publications - Franca Fagioli
University of Turin
17 shared publications - Katia Scotlandi
Laboratory of Oncology Research and Functional Genomics (ONCOGEN), IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
17 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (28) , 3113-3122
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials
PURPOSE: Outcome of patients with localized osteosarcoma is challenging. The role of mifamurtide is still a matter of debate. Two prospective trials were carried out in Italy (ISG/OS-2) and Spain (GEIS-33) with mifamurtide in ABCB1/P-glycoprotein (Pgp)–positive patients. PATIENTS AND METHODS: Patients age ≤40 years with localized extremity high-grade osteosarcoma were eligible. Analysis of Pgp expression from diagnostic biopsy was centralized. Patients received two cycles of preoperative methotrexate, doxorubicin, and cisplatinum (MAP) before surgery. Postoperatively, in case of Pgp overexpression (Pgp-positive), mifamurtide was added, combined with doxorubicin (one cycle) and four consecutive cycles of high-dose ifosfamide (HDIFO) for patients with poor histologic response, or with MAP in case of good response. Patients who were Pgp-negative received MAP postoperatively. We present the merged analysis of ISG/OS-2 and GEIS-33 trial, an observational study with same inclusion criteria and treatment of ISG/OS-2. The primary endpoint was 5-year event-free survival (EFS) according to the use of mifamurtide. Secondary endpoint was overall survival (OS). RESULTS: From March 2013 to April 2018, 398 patients were analyzed. The median age was 14 years (range, 4-40), male/female: 238/160 (1.48/1.0); 211 of 398 (53%) tumors were Pgp-positive, and 204 of 398 (51.3%) patients received mifamurtide. With a median follow-up of 70 months (IQR, 49-90 months), the 5-year EFS and OS were 65.2% (95% CI, 60.1 to 69.8) and 74.8% (95% CI, 69.8 to 79.0), respectively, with superior EFS for patients undergoing mifamurtide and chemotherapy as compared with EFS of patients undergoing chemotherapy alone (5-year EFS 71.4% v 58.3%; P = .0139) not confirmed at multivariable analysis ( P = .0593). CONCLUSION: In this merged analysis with a risk-adapted strategy for nonmetastatic osteosarcoma, the group with unfavorable prognoses, identified by Pgp expression, performed well when mifamurtide, combined with HDIFO in case of poor response, was administered after surgery.
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (28) , 3113-3122
Top Cited PapersOpen AccessIs There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials
PURPOSE: Outcome of patients with localized osteosarcoma is challenging. The role of mifamurtide is still a matter of debate. Two prospective trials were carried out in Italy (ISG/OS-2) and Spain (GEIS-33) with mifamurtide in ABCB1/P-glycoprotein (Pgp)–positive patients. PATIENTS AND METHODS: Patients age ≤40 years with localized extremity high-grade osteosarcoma were eligible. Analysis of Pgp expression from diagnostic biopsy was centralized. Patients received two cycles of preoperative methotrexate, doxorubicin, and cisplatinum (MAP) before surgery. Postoperatively, in case of Pgp overexpression (Pgp-positive), mifamurtide was added, combined with doxorubicin (one cycle) and four consecutive cycles of high-dose ifosfamide (HDIFO) for patients with poor histologic response, or with MAP in case of good response. Patients who were Pgp-negative received MAP postoperatively. We present the merged analysis of ISG/OS-2 and GEIS-33 trial, an observational study with same inclusion criteria and treatment of ISG/OS-2. The primary endpoint was 5-year event-free survival (EFS) according to the use of mifamurtide. Secondary endpoint was overall survival (OS). RESULTS: From March 2013 to April 2018, 398 patients were analyzed. The median age was 14 years (range, 4-40), male/female: 238/160 (1.48/1.0); 211 of 398 (53%) tumors were Pgp-positive, and 204 of 398 (51.3%) patients received mifamurtide. With a median follow-up of 70 months (IQR, 49-90 months), the 5-year EFS and OS were 65.2% (95% CI, 60.1 to 69.8) and 74.8% (95% CI, 69.8 to 79.0), respectively, with superior EFS for patients undergoing mifamurtide and chemotherapy as compared with EFS of patients undergoing chemotherapy alone (5-year EFS 71.4% v 58.3%; P = .0139) not confirmed at multivariable analysis ( P = .0593). CONCLUSION: In this merged analysis with a risk-adapted strategy for nonmetastatic osteosarcoma, the group with unfavorable prognoses, identified by Pgp expression, performed well when mifamurtide, combined with HDIFO in case of poor response, was administered after surgery.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Supplementary Figure S6: Venn diagram showing the 5 genes which are shared between the 21-gene signatureidentified in 62 primary osteosarcomas (discovery set) and the 31-gene signature related to the 33 osteosarcoma patients who underwent mifamurtide treatment
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Supplementary Figure S6: Venn diagram showing the 5 genes which are shared between the 21-gene signatureidentified in 62 primary osteosarcomas (discovery set) and the 31-gene signature related to the 33 osteosarcoma patients who underwent mifamurtide treatment
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Cox regression output , 31 genes selected based on LogRank≤0.05 significantly associated with overall survival (OS) in 33 localized primary high-grade osteosarcoma underwent chemotherapy (CT) combined with mifamurtide treatment
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Cox regression output , 31 genes selected based on LogRank≤0.05 significantly associated with overall survival (OS) in 33 localized primary high-grade osteosarcoma underwent chemotherapy (CT) combined with mifamurtide treatment
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
33 samples obtained from patients who underwent mifamurtide treatment. AUC value is shown. Optimal cut-off value used to stratify patients was 8.69
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
33 samples obtained from patients who underwent mifamurtide treatment. AUC value is shown. Optimal cut-off value used to stratify patients was 8.69
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Quantification of IHC stains referring to the mean number of positive cells/mm2.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Quantification of IHC stains referring to the mean number of positive cells/mm2.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Cox regression output , 21 genes selected based on LogRank≤0.05 significantly associated with overall survival (OS) in 62 localized primary high-grade osteosarcoma
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Cox regression output , 21 genes selected based on LogRank≤0.05 significantly associated with overall survival (OS) in 62 localized primary high-grade osteosarcoma
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Supplementary Figure S2:Overall survival of 62 patients with localized osteosarcoma (A) after a median follow-up of 107.8 months (IQR:92.5–128.4). (B) Overall survival for the 62 patients considered in the present study stratified as Pgp-positive and Pgp-negative (p = 0.6990).
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Supplementary Figure S2:Overall survival of 62 patients with localized osteosarcoma (A) after a median follow-up of 107.8 months (IQR:92.5–128.4). (B) Overall survival for the 62 patients considered in the present study stratified as Pgp-positive and Pgp-negative (p = 0.6990).
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Osteosarcoma prognostic signatures
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Osteosarcoma prognostic signatures
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Supplementary Figure S1: Study Design
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Supplementary Figure S1: Study Design
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Supplementary Figure S5: CIBERSORTx output of cell fraction deconvolution in the 62 primary Osteosarcoma of the discovery set.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Supplementary Figure S5: CIBERSORTx output of cell fraction deconvolution in the 62 primary Osteosarcoma of the discovery set.